CN107454844A - 用于癌症治疗的细胞治疗剂以及使用该细胞治疗剂的联合治疗 - Google Patents
用于癌症治疗的细胞治疗剂以及使用该细胞治疗剂的联合治疗 Download PDFInfo
- Publication number
- CN107454844A CN107454844A CN201680020932.XA CN201680020932A CN107454844A CN 107454844 A CN107454844 A CN 107454844A CN 201680020932 A CN201680020932 A CN 201680020932A CN 107454844 A CN107454844 A CN 107454844A
- Authority
- CN
- China
- Prior art keywords
- cancer
- cells
- cell
- anticancer
- msc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
Abstract
Description
Claims (17)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150031751 | 2015-03-06 | ||
KR10-2015-0031751 | 2015-03-06 | ||
PCT/KR2016/002188 WO2016144051A1 (ko) | 2015-03-06 | 2016-03-04 | 암 치료용 세포 치료제 및 이의 병용 요법 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107454844A true CN107454844A (zh) | 2017-12-08 |
Family
ID=56879471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680020932.XA Pending CN107454844A (zh) | 2015-03-06 | 2016-03-04 | 用于癌症治疗的细胞治疗剂以及使用该细胞治疗剂的联合治疗 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180037869A1 (zh) |
EP (1) | EP3266865B1 (zh) |
JP (1) | JP6474499B2 (zh) |
KR (1) | KR101850780B1 (zh) |
CN (1) | CN107454844A (zh) |
AU (1) | AU2016229710B2 (zh) |
BR (1) | BR112017019189A8 (zh) |
CA (1) | CA2978262C (zh) |
ES (1) | ES2861381T3 (zh) |
HK (1) | HK1245096A1 (zh) |
IL (1) | IL254228B (zh) |
NZ (1) | NZ735160A (zh) |
SG (1) | SG11201707134WA (zh) |
WO (1) | WO2016144051A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882274A (zh) * | 2019-10-21 | 2020-03-17 | 浙江生创精准医疗科技有限公司 | 间充质干细胞在降低地西他滨毒副作用的用途及相关药物 |
CN111671896A (zh) * | 2020-07-31 | 2020-09-18 | 北京广未生物科技有限公司 | 骨髓间充质干细胞和单克隆抗体联合治疗癌症的用途 |
CN116769724A (zh) * | 2023-08-17 | 2023-09-19 | 再少年(北京)生物科技有限公司 | 一种携带杀伤开关的间充质干细胞及其在肿瘤治疗中的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200005306A (ko) | 2018-07-06 | 2020-01-15 | 제주대학교 산학협력단 | 히스피딘을 포함하는 항암제 병용 투여용 약학적 조성물 |
JP7464977B2 (ja) | 2020-06-10 | 2024-04-10 | 国立大学法人東京農工大学 | イヌ中皮腫細胞株 |
JP7403438B2 (ja) * | 2020-12-24 | 2023-12-22 | 株式会社クボタ | 作業車 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009028870A2 (en) * | 2007-08-29 | 2009-03-05 | Medipost Co., Ltd. | Composition for the diagnosis, prevention or treatment of diseases related to cells expressing il-8 or gro-alpha, comprising ucb-mscs |
WO2011101834A1 (en) * | 2010-02-22 | 2011-08-25 | Advanced Neuro-Science Allies Private Limited | A method for obtaining mesenchymal stem cells, media, methods and composition thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007148802A (ru) * | 2005-06-02 | 2009-07-20 | Стемсайт, Инк. (Us) | Композиция пуповинной крови (варианты), способы ее получения и ее применение |
JP2007105037A (ja) * | 2005-09-16 | 2007-04-26 | Univ Of Tokyo | キメリズムを利用した幹細胞移植のための検査 |
KR101022401B1 (ko) * | 2005-09-29 | 2011-03-15 | 아주대학교산학협력단 | 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물 |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
AU2010325546B2 (en) * | 2009-11-27 | 2014-10-16 | Stempeutics Research Pvt. Ltd. | Methods of preparing mesenchymal stem cells, compositions and kit thereof |
US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
KR101371706B1 (ko) * | 2012-03-27 | 2014-03-12 | 중앙대학교 산학협력단 | 자살유전자를 발현하는 양수 유래 줄기세포 및 이를 포함하는 암 치료용 조성물 |
US20140065110A1 (en) * | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
-
2016
- 2016-03-04 SG SG11201707134WA patent/SG11201707134WA/en unknown
- 2016-03-04 US US15/554,849 patent/US20180037869A1/en active Pending
- 2016-03-04 KR KR1020160026281A patent/KR101850780B1/ko active IP Right Grant
- 2016-03-04 AU AU2016229710A patent/AU2016229710B2/en active Active
- 2016-03-04 NZ NZ735160A patent/NZ735160A/en not_active IP Right Cessation
- 2016-03-04 JP JP2017565032A patent/JP6474499B2/ja active Active
- 2016-03-04 EP EP16761938.6A patent/EP3266865B1/en active Active
- 2016-03-04 BR BR112017019189A patent/BR112017019189A8/pt active Search and Examination
- 2016-03-04 CA CA2978262A patent/CA2978262C/en active Active
- 2016-03-04 ES ES16761938T patent/ES2861381T3/es active Active
- 2016-03-04 WO PCT/KR2016/002188 patent/WO2016144051A1/ko active Application Filing
- 2016-03-04 CN CN201680020932.XA patent/CN107454844A/zh active Pending
-
2017
- 2017-08-30 IL IL254228A patent/IL254228B/en unknown
-
2018
- 2018-04-04 HK HK18104519.4A patent/HK1245096A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009028870A2 (en) * | 2007-08-29 | 2009-03-05 | Medipost Co., Ltd. | Composition for the diagnosis, prevention or treatment of diseases related to cells expressing il-8 or gro-alpha, comprising ucb-mscs |
WO2011101834A1 (en) * | 2010-02-22 | 2011-08-25 | Advanced Neuro-Science Allies Private Limited | A method for obtaining mesenchymal stem cells, media, methods and composition thereof |
Non-Patent Citations (3)
Title |
---|
吴陈欢: "脂质体介导胞嘧啶脱氨酶基因转染鼠骨髓间充质干细胞", 《中国组织工程研究与临床康复》 * |
沈历宗: "自杀基因联合化疗药物治疗结肠癌的体外研究", 《中华普通外科杂志》 * |
范存刚: "人脂肪源性间充质干细胞在实验性脑胶质瘤靶向治疗中的应用", 《中国现代神经疾病杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882274A (zh) * | 2019-10-21 | 2020-03-17 | 浙江生创精准医疗科技有限公司 | 间充质干细胞在降低地西他滨毒副作用的用途及相关药物 |
CN111671896A (zh) * | 2020-07-31 | 2020-09-18 | 北京广未生物科技有限公司 | 骨髓间充质干细胞和单克隆抗体联合治疗癌症的用途 |
CN116769724A (zh) * | 2023-08-17 | 2023-09-19 | 再少年(北京)生物科技有限公司 | 一种携带杀伤开关的间充质干细胞及其在肿瘤治疗中的应用 |
CN116769724B (zh) * | 2023-08-17 | 2023-10-27 | 再少年(北京)生物科技有限公司 | 一种携带杀伤开关的间充质干细胞及其在肿瘤治疗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2018508238A (ja) | 2018-03-29 |
BR112017019189A2 (pt) | 2018-04-24 |
EP3266865A1 (en) | 2018-01-10 |
EP3266865A4 (en) | 2018-09-05 |
KR101850780B1 (ko) | 2018-04-23 |
WO2016144051A1 (ko) | 2016-09-15 |
SG11201707134WA (en) | 2017-10-30 |
HK1245096A1 (zh) | 2018-08-24 |
IL254228B (en) | 2021-10-31 |
EP3266865B1 (en) | 2021-01-27 |
US20180037869A1 (en) | 2018-02-08 |
AU2016229710A1 (en) | 2017-09-28 |
KR20160108229A (ko) | 2016-09-19 |
IL254228A0 (en) | 2017-10-31 |
BR112017019189A8 (pt) | 2022-12-06 |
CA2978262A1 (en) | 2016-09-15 |
NZ735160A (en) | 2019-05-31 |
CA2978262C (en) | 2020-10-13 |
AU2016229710B2 (en) | 2019-05-09 |
ES2861381T3 (es) | 2021-10-06 |
JP6474499B2 (ja) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107454844A (zh) | 用于癌症治疗的细胞治疗剂以及使用该细胞治疗剂的联合治疗 | |
CN109837306A (zh) | 包载miRNA-204-5p的外泌体及其制备方法和应用 | |
CN102686264A (zh) | 用于具有增强的细胞滞留的靶向细胞递送的外部磁力 | |
CN114259476B (zh) | 一种调控巨噬细胞的纳米制剂及其制备方法与应用 | |
CN103656666A (zh) | 一种特异抑制肿瘤细胞转移的新型靶向肽tmtp1-kla的制备与应用 | |
CN114831931A (zh) | 一种具有抗肿瘤增效减毒效果的药用溶液及包含其的药用组合物 | |
CN107735097A (zh) | 用于治疗癌症或免疫性疾病的细胞外基质组合物 | |
CN110290786A (zh) | 用于预防或最小化上皮细胞-间充质细胞转换的方法和组合物 | |
CN109439665A (zh) | 一种靶向结合cd133蛋白的核酸适配体药物偶联物及其用途 | |
CN101919747A (zh) | 改良裸鼠结肠癌原位移植瘤模型的构建方法 | |
CN112137999A (zh) | 盐酸决奈达隆在制备抗消化道肿瘤药物中的应用 | |
CN101831405B (zh) | 肺靶向转移性人肝癌细胞株及其建立方法 | |
CN106924748A (zh) | 高穿透性肿瘤靶向脂质插件的构建及其促进细胞及细胞膜制剂向肿瘤聚集的作用 | |
CN108714149A (zh) | 地榆活性成分在制备抗肿瘤的药物中的用途 | |
CN107446024A (zh) | 一种可拮抗ddx3蛋白rna结合活性的多肽dip‑13及其应用 | |
CN106491630A (zh) | 一个新的靶向肝癌干细胞的miRNA的检测及应用 | |
Jin et al. | Combination of GNRs-PEI/cGAMP-laden macrophages-based photothermal induced in situ tumor vaccines and immune checkpoint blockade for synergistic anti-tumor immunotherapy | |
CN111840286B (zh) | 咳平及其盐在制备抗肿瘤药物中的应用 | |
CN108752426A (zh) | 带中性电荷的细胞穿透肽及作为细胞内运送载体的用途 | |
Zhang et al. | A Rat Model of Radiation Vasculitis for the Study of Mesenchymal Stem Cell‐Based Therapy | |
CN106619627A (zh) | 用于抑制消化道肿瘤干细胞增殖、分化和干性诱导的药物 | |
Van Thuy | Clinical Application of Mesenchymal Stem Cells for Cancer Therapy-A Review of Registered Clinical Trials | |
CN117180223A (zh) | 一种负载硝呋齐特的巨噬细胞递药系统及其应用 | |
Masule et al. | Utilization of stem cells for cancer treatment-A review | |
CN106310292B (zh) | 一种circRNA-CER基因的抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1245096 Country of ref document: HK |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220726 Address after: Gyeonggi Do, South Korea Applicant after: N4u technology holding academic cooperation fund Co.,Ltd. Address before: Gyeonggi Do, South Korea Applicant before: AJOU University INDUSTRY ACADEMIC COOPERATION FOUNDATION Effective date of registration: 20220726 Address after: Chonbei do, South Korea Applicant after: Brain rehabilitation Co.,Ltd. Address before: Gyeonggi Do, South Korea Applicant before: N4u technology holding academic cooperation fund Co.,Ltd. |